Skip to main content
OpenTrials
Completed

NCT Number: NCT05599958

Clinical and Genetic Profile of Pediatric Patients With Cystic Fibrosis in Sohag.

Cystic fibrosis (CF) is an autosomal recessive genetic disorder caused by mutations in the gene encoding CF transmembrane conductance regulator (CFTR), which is located at 7q31.2 and encodes 1480 amino acids. CFTR protein is responsible for regulating the transport of electrolytes and chloride across epithelial and mucus-producing cell membranes.

Completed

Looking for future studies?

Notify Me

Key information

Age range

2 day–18 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Sohag University Hospital

Sohag, Egypt

About this study

The discovery of the CFTR gene in the late 1980s triggered a surge of basic research that enhanced understanding of the pathophysiology and the genotype-phenotype relationships of this clinically variable disease of cystic fibrosis. More than 2000 variants of CFTR gene have been reported, and they are grouped to six classes depending on the pathophysiology of the CFTR protein ,The most common genetic defect reported in CF is the delta F508 mutation, Moreover, the degree of CF severity depends on the type of mutation, which typically affects the function and quantity of CFTR channels. When the CFTR protein is mutated, chloride ions accumulate in mucus-producing cells, resulting in a thick, sticky mucus that obstructs various pathways and hinders pulmonary, digestive, exocrine and male reproductive functions. Furthermore, mucus buildup increases a patient's susceptibility to airway obstruction, bacterial lung infection, pancreatic insufficiency, malabsorption and infertility. CF is characterized by significant clinical heterogeneity.

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Children and adolescents aged 2 days - 18 year.
  • patients clinically suspected or diagnosed with cystic fibrosis
  • patients diagnosed with cystic fibrosis and attending or referred to the Pediatric pulmonology clinic at Sohag University Hospital.

Exclusion criteria

  • Patient with cystic fibrosis like symptoms with another confirmed diagnosis ex. primary ciliary dyskinesia

Treatment and study plan

sweat chloride test

Diagnostic Test

assessing chloride (Cl-) concentration in sweat of the patient

Genetic Testing

Genetic

detection of CFTR mutation

Primary outcomes

  1. number of patients presented with each presenting symptoms and signs .

    Time frame: 6 months

    number of patients with each main presenting symptoms of cystic fibrosis as respiratory distress ,dehydration or others .

  2. number of patients affected with different genetic mutations causing cystic fibrosis.

    Time frame: 6 months

    detecting the different genetic mutations affecting pediatric patients in Sohag

Sponsors and collaborators

Lead sponsor

Sohag University

Other

Registry information

Important dates

Study start
2022
Primary completion
2023
Study completion
2023
First posted
Oct 31, 2022
Registry last updated
Nov 2, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.